Terns Pharmaceuticals, Inc. (NASDAQ:TERN) has seen a significant climb of 629.64 percent in 2025, driven by positive results from the clinical trial of its therapy candidate for chronic myeloid leukemia (CML). At the recent ASH Annual Meeting, Terns reported a 64 percent improvement in CML patients after 24 weeks of treatment with TERN-701.

Following successful trial results, Terns Pharmaceuticals, Inc. (NASDAQ:TERN) raised $747.5 million through the issuance of over 18.68 million shares. The funds will support the development, manufacturing, and future commercial launch of TERN-701, with additional capital allocated for working capital and general corporate purposes. The company’s strong performance has garnered investor interest and support.

Read more at Yahoo Finance: Tern Pharmaceuticals (TERN) Soars 630% on CML Treatment Best-in-Class Potential